



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

MUT/MIN/2023/02

COMMITTEE ON MUTAGENICITY OF CHEMICALS IN FOOD, CONSUMER PRODUCTS AND THE ENVIRONMENT

Minutes of the meeting held at 10.30 on 15th June 2023 via MS Teams.

Present:

Chairman: Professor G Jenkins

Members: Mr A Bhagwat
Dr C Beevers
Dr A Doherty (Co-opted member)
Dr P Fowler
Dr N Goldsmith (Associate member)
Dr G Johnson
Professor D Harrison (Ex officio)
Ms J Kenny
Dr A Povey
Mr P Rawlinson
Mrs M Wang

Secretariat: Dr O Sepai (UKHSA Scientific Secretary)
Mr S Robjohns (UKHSA Secretariat)
Ms B Gadeberg (UKHSA Secretariat)
Dr D Gott (FSA Secretariat)
Ms C Tsoulli (FSA)
Dr C Mulholland (FSA)
Ms C Potter (FSA)

Secretariat Support: Dr R Bevan (IEH Consulting)
Dr S Bull (Tara Consulting)

Assessors: Ms A Baker (VMD)
Ms N Hough (HSE)
Ms A Baker (VMD)
Dr J Clements (MHRA)
Ms H Alpren (DEFRA)

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

Observers:

Ms K Boss (FSS)
Dr J Weeks (IEH Consulting)
Paula Braun (PETA)

		Paragraph
1.	Welcome and Apologies for absence	1
2.	Announcements	2
3.	Minutes of the meeting held on 23 rd February 2023 (MUT/MIN/2023/01)	5
4.	Matters Arising	6
5.	Draft non-expert summaries for COM statements (MUT/2023/05)	7
6.	What's on the Horizon – Presentation by Jason Weeks - IEH	11
7.	NC3Rs/Unilever Workshop “Opportunities for the UK to develop world leading chemicals regulation” – Summary and Presentation by Natalie Burden (NC3Rs)	12
8.	QSARs – The Way forward presentation – Paul Fowler (COM)	17
9.	Draft COM Annual report 2022	18
10.	OECD Updates	19
11.	AOB	21
12.	Date of next meeting	22

60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77

78

79

ITEM 1: WELCOME AND APOLOGIES FOR ABSENCE

80

81

1. The Chair welcomed the COM members, assessors and secretariat. The Chair also welcomed Dr Ruth Bevan from IEH Consulting providing support to the COM secretariat. Apologies for absence were received from the COM member Professor Shareen Doak and the assessors Ms F Fernandez (VMD) and Dr L Koshy (HSE).

86

87

88

ITEM 2: ANNOUNCEMENTS

89

90

2. Members were requested to declare any interests before the discussion of any items.

92

93

3. The Chair informed the COM that the members Julie Kenny and George Johnson and Madeleine Wang had come to the end of their initial 3-year term and that all three had their term as a COM member rolled over into a second term. The advert for the two vacant members positions had gone live.

97

98

4. The COM had already recruited Nathan Goldsmith as an associate member and was looking to recruit another associate member. Members were requested to use their networks to inform people who were interested to look out for this opportunity when the advert comes out.

100

101

102

103

104

ITEM 3: MINUTES OF THE MEETING HELD ON 23rd February 2023 (MUT/MIN/2022/03)

105

106

107

5. The minutes of the COM meeting held on the 23rd of February 2023 were agreed subject to minor typographical amendments.

108

109

110

111

ITEM 4: MATTERS ARISING

112

113

6. The Food standards Agency (FSA) provided an update on the progress of the COM sub-group on the evaluation of the genotoxicity of titanium oxide. The COM sub-group had read through the identified papers and sifted through using the previously agreed criteria and scoring system. The papers were sifted based on quality with the aid of a colour coded system of red, amber and green, with studies flawed in a major way coded as red. The good quality studies would be prioritised, and an initial draft review would be produced based on these. It was noted that there were far fewer *in vivo* studies than *in vitro* studies. IEH secretariat support informed the COM that the review process had initially started with approximately 270 papers from the EFSA report with some of these being duplicates. Following the first round of sifting, approximately 62 papers remained. Following a second round of screening, which considered aspects such as methodology, agglomeration, and identification of the test substance, approximately 34 studies remained. Following more in-depth consideration, approximately 17 were considered to be unsuitable, 8 amber and only 9 as acceptable. The COM sub-group would draft an evaluation based on the

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129 remaining acceptable papers and intended to produce this report for the COM
130 October 2023 meeting.

131

132 **ITEM 5: DRAFT NON-EXPERT SUMMARIES FOR COM STATEMENTS**
133 **(MUT/2023/05)**

134

135 7. No interests were declared for this item.

136

137 8. At the COM meeting in June 2022, it was agreed that the public could
138 benefit from the addition of non-expert summaries placed at the start of each
139 COM guidance statement (GS). Paper MUT/2023/05 discussed a third draft non-
140 expert summary for the overarching COM GS entitled 'Guidance on a strategy
141 for genotoxicity testing of chemicals'. This paper had previously been amended
142 following comments from Members when presented at the meeting in October
143 2022 (MUT/2022/13) and February 2023 (MUT/2022/03) and by a lay member
144 of COM following the meeting in February 2023.

145

146 9. Members discussed the importance of layering information when
147 communicating with the public, which would enable readers to access the
148 content of the COM publications at their individual level of
149 understanding/education. The amended non-expert summary for the
150 overarching COM guidance statement was considered to be appropriate in style
151 for a mid-level introductory document, aimed at individuals achieving an A level
152 (or equivalent) standard of education. However, it was also considered that an
153 entrance level summary would need to be written, which should be aimed at
154 GCSE level of education; this would be best placed on the UKHSA public facing
155 website when it had been developed.

156

157 10. Members suggested a number of amendments to the draft paper for
158 clarification purposes. It was considered that once the format and style of the
159 non-expert summary was agreed for the over-arching guidance statement, this
160 could then be applied to the remaining COM guidance statement series.
161 Members agreed that draft paper should be amended according to discussions
162 and sent to the committee for any further comments via email

163

164

165 **ITEM 6: WHAT IS ON THE HORIZON – PRESENTATION BY JASON WEEKS**
166 **FROM IEH (MUT/2023/02)**

167

168 11. A presentation on the utility, benefits and methodologies for developing
169 a horizon scanning activity using a structured and focussed approach was
170 shared with committee members. The suggested methodology provided a
171 framework using a STEEPLE (Social, Technological, Economic,
172 Environmental, Political, Legal and Ethical) approach to address key drivers
173 impacting future outcomes. For example, by the incorporation of societal
174 aspects and ethics in developing insights based on public attitudes and
175 perceptions that may influence future committee decision making. A systematic
176 and structured evaluation of current information to identify emerging threats
177 and risk was suggested as a method that would allow for better preparedness
178 and ability to introduce mitigation approaches. A successful horizon scanning
179 approach should be continuous and allow searching for information that was
180 not known. There would be a requirement to prioritise and filter information and

181 thought would be required on how to communicate the results. It was agreed
182 by COM that further discussion would take place to define the activities to be
183 taken forward probably as a collective Committee task with the sister
184 committees on toxicity (COT) and carcinogenicity (COC) rather than specific
185 activity for COM. This could be more efficient in terms of transfer of knowledge
186 across the committees.

187
188
189

190 **ITEM 7: NC3RS/UNILEVER WORKSHOP “OPPORTUNITIES FOR THE UK**
191 **TO DEVELOP WORLD-LEADING CHEMICALS REGULATION” –**
192 **SUMMARY PRESENTATION BY NATALIE BURDEN (NC3RS)**
193

194 12. Dr Natalie Burden presented a summary of a workshop on the 11th of
195 May 2023 held jointly by the NC3Rs and Unilever to discuss opportunities the
196 UK may have, due to EU-exit, to develop world-leading chemicals regulation
197 that could help reduce the reliance on animal testing. The aim of the workshop
198 was to establish a consensus 5-year vision from the UK science base for a
199 future UK chemicals policy, and attendees included representatives of industry,
200 government, contract research organisations, trade associations and
201 academia.

202

203 13. A draft 5-year vision had been prepared by the NC3Rs in conjunction
204 with a steering group which formed the basis of the workshop discussions. Key
205 features of the draft vision were that it covered a short time period, was
206 science-led, embraced current scientific developments, beneficial to the UK
207 economy, in line with sustainability goals and maximised opportunities to apply
208 the 3Rs whilst ensuring maximum protection of human health and the
209 environment. This vision also intended to complement the science and
210 technology framework document published by the current government, which
211 outlined UK plans to become a science and technology superpower by 2030.

212

213 14. A tiered approach was proposed that utilises multiple lines of evidence,
214 including existing information and those from evolving methodologies such as
215 NAMs, which are integrated to help build confidence in using non-traditional
216 approaches to risk assessment. The approach has a degree of flexibility to
217 exploit advances in technologies and can be adjusted for sector specific
218 differences. Attendees were in general agreement of the drafted approach and
219 supported a move away from the current hazard identification approach for risk
220 assessment. Attendees also ideally wanted a harmonised approach with
221 mutual recognition avoiding different testing requirements in different parts of
222 the world. However, it was recognised that this is not a small undertaking and
223 dedicated funding and capability would be needed to help lead these cutting-
224 edge approaches and innovation within the current approaches.

225

226 15. To realise the 5-year vision, attendees considered that a clear definition
227 of the benefit propositions was needed to improve scientific rationale towards
228 safety assessment, whilst retaining public confidence and protection. In
229 addition, it was seen that there is a need for accountability and a political will to
230 own and direct this vision and that there is currently an opportunity for different
231 regulatory departments to be more collaborative. It was proposed that a UK
232 centre of excellence could be established, as has been done in other countries,

233 which would act as a link between method developers and the regulators. The
234 next steps from the NC3Rs and subgroup committee was to prepare a
235 workshop report and to draft a policy paper, based on the main discussion
236 points and recommended actions, to be presented to a government
237 department.

238

239 16. The Chair thanked the speaker for the presentation and summary and
240 commented that it was very useful for COM to have an early overview of the
241 workshop discussions. It was suggested that the draft policy document should
242 also be seen by COM at future meetings. During discussions, COM members
243 considered that a proof of concept and a coordinated approach was needed for
244 the proposed approach, as currently there are a number of different initiatives
245 underway by different organisations both in the UK and globally. Ownership of
246 the 5-year vision would help focus this for the UK and there was a need to
247 ensure that any message was getting to the correct people. Members
248 considered that there was now an opportunity for the UK to influence and bring
249 onboard scientifically justified changes to regulatory approaches.

250

251 **ITEM 8: QSARS – THE WAY FORWARD – PAUL FOWLER (COM)**

252

253 17 One member Paul Fowler had been asked to lead a COM sub-group on
254 QSARS a gave a presentation. It was noted that QSAR data would only
255 improve and likely very quickly. For example, clastogenicity was better
256 predicted that it had been previously. There was a request for members to
257 volunteer to participate in the planned QSAR sub-group. It was suggested that
258 the COM would consider QSARS with a focus on pragmatic guidance on how
259 to use QSARS for the evaluation of the mutagenicity of impurities. There would
260 also be an update produced on the predictivity of QSARS for all mutagenic
261 endpoints, for example, to assess whether all the mutagenic endpoints were
262 adequately covered. The updated COM guidance would also be aligned with
263 existing guidance. It was intended that recent literature would be considered
264 and that a draft document would be produced in 2024.

265

266 **ITEM 9: DRAFT COM ANNUAL REPORT 2022**

267

268

269 18. A draft COM annual report had been produced that summarised the
270 topics and areas of work considered by the COM through 2022. Members were
271 requested to provide any comments on this draft document to the secretariat.

272

273 **ITEM 10: OECD UPDATES**

274

275 19. Members were informed that the OECD test guideline on the *in vitro*
276 micronucleus test was in the process of being updated in relation to the wording
277 and guidance on cytotoxicity. The COM was also informed that there would be
278 an OECD review of the Toxtracker assay and interested members were
279 encouraged to sign up to the peer review process. Additionally, it was noted that
280 there was likely to be a wider review of historical control data in terms of how it
281 is collected and maintained. It was also noted that the OECD would likely
282 undertake a review of genotoxicity historical control data. This could potentially
283 be extended to a review of historical control data in general at a later date.

284

285 20. The International workshop on Genotoxicity Testing (IWGT) had agreed
286 that the *in vivo* liver micronucleus test was sufficiently robust to warrant the
287 development of an OECD Test Guideline. Members were also informed that at
288 a Health and Environmental Sciences Institute (HESI) meeting there was some
289 discussion over how best to develop OECD Guidelines on the use of error
290 corrected duplex sequencing.

291

292 **ITEM 11: AOB**

293

294 21. Members were asked to check that their declaration of interests were up
295 to date.

296

297 **ITEM 12: DATE OF NEXT MEETING**

298

299 22. Date of the next meeting 12th October 2023.

300

301

302